No Data
No Data
Peeling Back The Layers: Exploring Exact Sciences Through Analyst Insights
Analysts' ratings for Exact Sciences (NASDAQ:EXAS) over the last quarter vary from bullish to bearish, as provided by 8 analysts.In the table below, you'll find a summary of their recent ratings,
Exact Sciences Is Maintained at Buy by Goldman Sachs
Exact Sciences Is Maintained at Buy by Goldman
Express News | Goldman Sachs Maintains Buy on Exact Sciences, Lowers Price Target to $75
Exact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer Screening
Since its launch in 2022, the FOCUS Program has awarded more than $4.5 million to over 75 organizations throughout the United StatesMADISON, Wis.--(BUSINESS WIRE)--Exact Sciences, a leading provider
Exact Sciences Corporation (EXAS) Slipped Over Investors' Concerns
These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird
Baboompiak : yup holding onto 100 shares at 57.5